Zhang Chun, Wu Qing-Bai
Pediatrics Department, Lianshui County People's Hospital, Huai'an, China.
Medicament Department, The Second People's Hospital of HUAI'AN, Huai'an, China.
Pak J Pharm Sci. 2022 Sep;35(5):1407-1414.
The principal objective of our study was to investigate the safety and efficacy of Clostridium butyricum enterococci triple viable vs Bifidobacterium triple viable in the cure of bronchial asthma in children, and to compare the serum immune indexes. We retrospectively investigated 180 children with BA treated in Lianshui County People's Hospital from June 2019 to June 2021. These children were divided into three groups in accordance with the cure methods: The control group (group A) gave consent to routine drug treatment, the children in the Clostridium butyricum enterococci triple viable group (group B) received routine treatment, combined with Clostridium butyricum enterococci triple viable tablets and the children in the Bifidobacterium Lactobacillus triple viable group (group C) received routine treatment, combined with Bifidobacterium Lactobacillus triple viable powder. Combined with the treatment results, the effect of combined probiotics on BA in children is more significant than that of routine treatment, which can effectively enhance the immune function, lung function and inflammation of children. The effect of Clostridium butyricum enterococci triple viable bacteria is better than that of Bifidobacterium triple viable bacteria.
我们研究的主要目的是调查丁酸梭菌肠球菌三联活菌与双歧杆菌三联活菌在治疗儿童支气管哮喘方面的安全性和有效性，并比较血清免疫指标。我们回顾性调查了2019年6月至2021年6月在涟水县人民医院接受治疗的180例哮喘患儿。这些患儿根据治疗方法分为三组：对照组（A组）同意接受常规药物治疗，丁酸梭菌肠球菌三联活菌组（B组）的患儿接受常规治疗，并联合丁酸梭菌肠球菌三联活菌片，双歧杆菌乳杆菌三联活菌组（C组）的患儿接受常规治疗，并联合双歧杆菌乳杆菌三联活菌散。结合治疗结果，联合益生菌对儿童哮喘的治疗效果比常规治疗更显著，可有效增强儿童的免疫功能、肺功能并减轻炎症。丁酸梭菌肠球菌三联活菌的效果优于双歧杆菌三联活菌。
